Case Based Peer Perspectives: Metastatic Castration-Resistant Prostate Cancer
Case: A 69-Year-Old Man With mCRPC Progressing on Therapy
July 2016
H&P:
Treatment:
March 2017
8 months later, patient complained of fatigue and mild back discomfort
Treatment:Enzalutamide
March 2018
April 2018
April 2019
One year later patient presented with increased lower back discomfort causing disruption in daily activity.
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More